ICON Public Limited Company
ICLR
주식 순위
#1607
ICON Public Limited Company, a clinical research organization, provides... ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
주가
$175.51
시가총액
$13.54B
변동 (1일)
4.38%
변동 (1년)
-6.87%
국가
IE
거래 ICON Public Limited Company (ICLR)
카테고리
Healthcare
ICON Public Limited Company (ICLR)의 P/E 비율
October 2026 기준 P/E 비율 TTM: 39.38
ICON Public Limited Company의 최신 재무 보고서와 주가에 따르면 현재 P/E (TTM) 비율은 39.38입니다. 2023년 말 기준 P/E 비율은 37.95였습니다.
ICON Public Limited Company의 P/E 비율 기록 (2001 ~ 2026)
매년 말 P/E 비율
| 연도 | P/E 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 39.38 | 80.24% |
| 2024 | 21.85 | -42.42% |
| 2023 | 37.95 | 21.09% |
| 2022 | 31.34 | -76.90% |
| 2021 | 135.68 | 331.54% |
| 2020 | 31.44 | 26.76% |
| 2019 | 24.80 | 14.51% |
| 2018 | 21.66 | -1.60% |
| 2017 | 22.01 | 38.92% |
| 2016 | 15.85 | -16.84% |
| 2015 | 19.06 | 4.81% |
| 2014 | 18.18 | -24.06% |
| 2013 | 23.94 | -20.29% |
| 2012 | 30.04 | -33.47% |
| 2011 | 45.15 | 200.61% |
| 2010 | 15.02 | 11.16% |
| 2009 | 13.51 | -7.96% |
| 2008 | 14.68 | -7.47% |
| 2007 | 15.87 | 13.86% |
| 2006 | 13.93 | -38.57% |
| 2005 | 22.68 | 356.33% |
| 2004 | 4.97 | 12.27% |
| 2003 | 4.43 | -18.73% |
| 2002 | 5.45 | -20.05% |
| 2001 | 6.81 | 0.00% |
유사 기업 또는 경쟁사의 P/E 비율
| 회사 | P/E 비율 | P/E 비율 차이 | 국가 |
|---|---|---|---|
| 36.15 | -8.20% |
US
|
|
| 39.77 | 0.99% |
US
|
|
| -290.26 | -837.01% |
US
|
|
| - | - |
CN
|
|
| 34.18 | -13.20% |
US
|
P/E 비율 읽는 방법
P/E 비율은 회사의 주가와 주당순이익 간의 관계를 측정합니다.
낮지만 양수인 P/E는 현재 가치 대비 높은 수익을 내고 있는 저평가된 기업을 의미합니다. 높은 음수(0에 가까운) P/E는 큰 손실을 나타냅니다.
P/E가 30을 초과하거나 음수인 기업은 일반적으로 '성장주'로 간주되며, 투자자들은 향후 수익성 개선을 기대합니다.
양의 P/E가 10 미만인 기업은 일반적으로 '가치주'로 간주되며, 이미 매우 수익성이 높고 향후 큰 성장은 기대되지 않습니다.